<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00089193</url>
  </required_header>
  <id_info>
    <org_study_id>10524</org_study_id>
    <secondary_id>UVACC-MEL-43</secondary_id>
    <secondary_id>FCCC-03045</secondary_id>
    <secondary_id>MDA-2003-0720</secondary_id>
    <nct_id>NCT00089193</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma</brief_title>
  <official_title>Evaluation of GM-CSF-in-Adjuvant and the Number of Vaccine Sites on Immunization With Multiple Synthetic Melanoma Peptides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig L Slingluff, Jr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
      Colony-stimulating factors such as sargramostim may increase the number of immune cells found&#xD;
      in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a&#xD;
      stronger immune response and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying vaccine therapy and sargramostim to see&#xD;
      how well they work compared to vaccine therapy alone in treating patients with stage II B,&#xD;
      stage IIC, stage III, or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare immune response in patients with stage IIB-IV melanoma treated with vaccination&#xD;
           comprising multiple synthetic melanoma peptides and Montanide ISA-51 with vs without&#xD;
           sargramostim (GM-CSF).&#xD;
&#xD;
        -  Compare immune response in patients treated with these vaccinations administered at 1 vs&#xD;
           2 sites.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label study. Patients are randomized to 1 of 4 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive vaccination comprising multiple synthetic melanoma peptides and&#xD;
           Montanide ISA-51 at 1 injection site.&#xD;
&#xD;
        -  Arm II: Patients receive vaccination comprising multiple synthetic melanoma peptides and&#xD;
           Montanide ISA-51 at 2 injection sites.&#xD;
&#xD;
        -  Arm III: Patients receive vaccination comprising multiple synthetic melanoma peptides,&#xD;
           Montanide ISA-51, and sargramostim (GM-CSF) at 1 injection site.&#xD;
&#xD;
        -  Arm IV: Patients receive vaccination comprising multiple synthetic melanoma peptides,&#xD;
           Montanide ISA-51, and GM-CSF at 2 injection sites.&#xD;
&#xD;
      In all arms, treatment repeats once weekly for 6 weeks. Patients return for booster&#xD;
      vaccinations at weeks 12, 26, 39, and 52.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 124 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>multi-epitope melanoma peptide vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of melanoma&#xD;
&#xD;
               -  Stage IIB, IIC, III, or IV disease&#xD;
&#xD;
          -  Must express HLA-A1, -A2, or -A3&#xD;
&#xD;
          -  No ocular melanoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  12 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Liver function tests ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell or squamous cell skin&#xD;
             cancer without brain metastasis, carcinoma in situ of the breast, or carcinoma in situ&#xD;
             of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior growth factors&#xD;
&#xD;
          -  More than 4 weeks since prior allergy shots&#xD;
&#xD;
          -  No prior vaccine therapy for melanoma or any other cancer with any of the peptides&#xD;
             used in this study&#xD;
&#xD;
          -  More than 12 weeks since prior melanoma vaccine therapy* NOTE: *Prior melanoma vaccine&#xD;
             allowed only for patients with disease progression during or after administration of&#xD;
             the vaccine&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig L. Slingluff, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington Cancer Institute at Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center at University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center at the University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Professor, Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

